Testing a blood marker for liver cancer blood clots
Part of Cancer, Digestive system clinical trials.
This study looks at whether a substance in the blood called PIVKA-II can predict blood clots in the main vein of the liver (portal vein) in people with liver cancer. Participating could help doctors better identify who might develop this complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (HCC).
- You have not had prior local treatment (like tumor ablation or chemo into the liver) or a liver transplant.
- You are not currently taking vitamin K, blood thinners like warfarin, or antibiotics.
- You do not have jaundice (from bile duct blockage) or kidney problems.
- You have no other types of cancer besides liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
This study looks at two blood markers (AFP and PIVKA-II) in people getting a liver transplant for liver cancer. It aims to see if these markers can predict how well patients do after the transplant, which may help guide future treatment decisions.
This study is following people with cirrhosis to see how often they get a blood clot in the liver's main vein (portal vein) and whether using blood thinners helps. If you have cirrhosis, joining this study could help doctors learn better ways to prevent and treat these clots.
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
This trial studies how your blood's ability to clot changes over time in people with certain cancers who have not yet started treatment. The goal is to better predict who might develop a dangerous blood clot, so that preventative steps can be taken.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.